Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® ( vadadustat ) Across All IRC Dialysis Clinics - Akebia Therapeutics ( NASDAQ:AKBA )
CAMBRIDGE, Mass. and FRANKLIN, Tenn., Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc.
Akebia ( AKBA ) Q2 Revenue Jumps 43%
Akebia Therapeutics ( NASDAQ:AKBA ) , a biopharmaceutical company specializing in kidney disease treatments, reported its earnings on August 7, 2025, covering results for the quarter. The headline news was a marked upturn in revenue and a transition to positive GAAP net income.
Akebia Therapeutics ( AKBA ) Reports Break-Even Earnings for Q2
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of +100.00% and +33.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
OmniAb, Inc. ( OABI ) Reports Q2 Loss, Lags Revenue Estimates
OmniAb, Inc. (OABI) delivered earnings and revenue surprises of -7.14% and -35.71%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Akebia Initiates Vafseo® ( vadadustat ) Post-Marketing Study in Conjunction with Large Dialysis Organization - Akebia Therapeutics ( NASDAQ:AKBA )
CAMBRIDGE, Mass., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc. AKBA, a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a post-marketing study to identify additional potential benefits of ...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CAMBRIDGE, Mass., Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc. ( Nasdaq: AKBA ) , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 238,500 shares of ...
Are Medical Stocks Lagging Akebia Therapeutics ( AKBA ) This Year?
Here is how Akebia Therapeutics (AKBA) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer - Vor Biopharma ( NASDAQ:VOR )
Dr. Zuraw led clinical development of telitacicept across MG, Sjögren's, SLE, and RA at RemeGen, resulting in multiple regulatory approvals in China; brings deep U.S. and global development experience to support Vor Bio's new development focus and execution of late-stage programs
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
CAMBRIDGE, Mass., July 17, 2025 ( GLOBE NEWSWIRE ) -- Vor Bio ( Nasdaq: VOR ) , a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Qing Zuraw, M.D., M.P.H., M.B.A., as Chief Development Officer, effective immediately.
Akebia Therapeutics ( AKBA ) Upgraded to Strong Buy: Here's What You Should Know
Akebia Therapeutics (AKBA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Akebia Therapeutics ( AKBA ) Stock Outpacing Its Medical Peers This Year?
Here is how Akebia Therapeutics (AKBA) and ResMed (RMD) have performed compared to their sector so far this year.
Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
CAMBRIDGE, Mass., July 08, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc. ( Nasdaq: AKBA ) , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Nik Grund, Chief Commercial Officer, will participate in a Fireside Chat ...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Akebia Therapeutics ( NASDAQ:AKBA )
CAMBRIDGE, Mass., July 01, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc. AKBA, a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 141,800 shares of Akebia's common ...
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors - Avalo Therapeutics ( NASDAQ:AVTX )
WAYNE, Pa., June 18, 2025 ( GLOBE NEWSWIRE ) -- Avalo Therapeutics, Inc. AVTX, a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors.
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology
Akebia continues to publish important, clinically relevant data to further physicians' understanding of Vafseo® ( vadadustat ) Akebia continues to publish important, clinically relevant data to further physicians' understanding of ...
Akebia Therapeutics ( AKBA ) Q1 Earnings and Revenues Top Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 200% and 26.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Xencor ( XNCR ) Reports Q1 Loss, Tops Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of -4.76% and 48.38%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics ( AKBA ) Expected to Beat Earnings Estimates: Should You Buy?
Akebia Therapeutics (AKBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why You Shouldn't Bet Against Akebia Therapeutics ( AKBA ) Stock
Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering
AKBA's shares fell after announcing the pricing of its secondary issue of shares, which were at a discount to the previous closing price.
Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase - Benson Hill ( NASDAQ:BHIL ) , Akebia Therapeutics ( NASDAQ:AKBA )
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded up 0.63% to 42,230.78 while the NASDAQ climbed 0.81% to 17,894.89. The S&P 500 also rose, gaining, 0.61% to 5,710.13. Communication services shares rose by 1.4% on ...
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Akebia Therapeutics ( NASDAQ:AKBA ) , Enerflex ( NYSE:EFXT )
U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Thursday. Shares of JOYY Inc. YY fell sharply in today's pre-market trading following weak quarterly sales. JOYY reported quarterly earnings of $1.77 per share which beat the analyst consensus estimate ...
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., March 19, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc. ( "Akebia" ) ( Nasdaq: AKBA ) , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the pricing of its underwritten public offering ( the ...
Akebia Therapeutics Announces Proposed Public Offering of Common Stock - Akebia Therapeutics ( NASDAQ:AKBA )
CAMBRIDGE, Mass., March 19, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc. ( "Akebia" ) AKBA, a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has commenced an underwritten public offering ( the "Offering" ) .
Hallador Energy, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Akebia Therapeutics ( NASDAQ:AKBA ) , Arlo Technologies ( NYSE:ARLO )
U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Tuesday. Shares of Hallador Energy Company HNRG fell sharply in today's pre-market trading following a fourth-quarter sales miss.
Akebia Therapeutics ( AKBA ) Reports Q4 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -25% and 18.21%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for January 3rd
AKBA, KOF and GES have been added to the Zacks Rank #24 (Strong Sell) List on January 3, 2024.
New Strong Sell Stocks for December 5th
AKBA, KOF and XRAY have been added to the Zacks Rank #5 (Strong Sell) List on December 5, 2024.
New Strong Sell Stocks for November 22nd
ATI, AKBA and ALTG have been added to the Zacks Rank #5 (Strong Sell) List on November 22, 2024.
Akebia Therapeutics ( AKBA ) Reports Q3 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -100% and 18.03%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® ( vadadustat ) for Patients on Dialysis - Akebia Therapeutics ( NASDAQ:AKBA )
Contract in place with a comprehensive kidney care provider serving more than 200,000 patients at its thousands of U.S. dialysis centers CAMBRIDGE, Mass., Oct. 22, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc.
Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® ( vadadustat ) for Patients on Dialysis - Akebia Therapeutics ( NASDAQ:AKBA )
U.S. Renal Care is a leading provider of in-center and home dialysis in the United States CAMBRIDGE, Mass., Oct. 7, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. AKBA, a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S.
Is Entera Bio ( ENTX ) Outperforming Other Medical Stocks This Year?
Here is how Entera Bio Ltd. (ENTX) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
Here's Why You Should Consider Buying Akebia ( AKBA ) Stock
Here, we discuss some reasons why buying Akebia (AKBA) stock now may turn out to be a prudent move.
Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia
Corcept, Amneal, Bioventus, Foghorn and Akebia have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Buy as Innovation Reaches Peak
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.
Are Medical Stocks Lagging Acrivon Therapeutics, Inc. ( ACRV ) This Year?
Here is how Acrivon Therapeutics, Inc. (ACRV) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
Akebia Therapeutics ( AKBA ) Reports Q2 Loss, Lags Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 33.33% and 4.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate ( OLC )
- Patients preferred OLC more than 4 to 1 over their prior phosphate binder therapy ...
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
BOSTON, June 28, 2024 ( GLOBE NEWSWIRE ) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its board ...
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors - Verve Therapeutics ( NASDAQ:VERV )
BOSTON, June 28, 2024 ( GLOBE NEWSWIRE ) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its board ...
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer
CAMBRIDGE, Mass., June 24, 2024 /PRNewswire/ -- ( Nasdaq: AKBA ) , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Erik Ostrowski as Senior Vice President, Chief Financial Officer and Chief Business Officer.
Akebia Therapeutics ( AKBA ) Reports Q1 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 0% and 20.72%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Akebia to host conference call at 8:00 a.m. ET on May 9 CAMBRIDGE, Mass., May 9, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. ( Nasdaq: AKBA ) , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the first ...
ALNY: 4 Biotech Stocks to Watch Closely in May
As biotechnology continues to propel breakthroughs in pharmaceuticals, genomics, and medical devices, the spotlight is increasingly drawn to this sector for growth and portfolio diversification.
Akebia Therapeutics ( NASDAQ:AKBA ) Lowered to "Hold" at StockNews.com
StockNews.com lowered shares of Akebia Therapeutics ( NASDAQ:AKBA - Free Report ) from a buy rating to a hold rating in a research report released on Monday. Separately, HC Wainwright upped their price objective on Akebia Therapeutics from $5.00 to $6.00 and gave the company a buy rating in a ...
StockNews.com Upgrades Akebia Therapeutics ( NASDAQ:AKBA ) to "Buy"
Akebia Therapeutics ( NASDAQ:AKBA - Get Free Report ) was upgraded by StockNews.com from a "hold" rating to a "buy" rating in a research report issued on Friday. Separately, HC Wainwright increased their price objective on Akebia Therapeutics from $5.00 to $6.00 and gave the company a "buy" ...
Akebia Therapeutics ( NASDAQ:AKBA ) Downgraded by StockNews.com
Akebia Therapeutics ( NASDAQ:AKBA - Get Free Report ) was downgraded by research analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Thursday.
Akebia Therapeutics ( NASDAQ:AKBA ) Upgraded by StockNews.com to Buy
Akebia Therapeutics ( NASDAQ:AKBA - Get Free Report ) was upgraded by equities research analysts at StockNews.com from a "hold" rating to a "buy" rating in a note issued to investors on Wednesday.
Why Is Akebia Therapeutics Stock Trading Higher On Thursday? - Akebia Therapeutics ( NASDAQ:AKBA )
Wednesday, the FDA approved Akebia Therapeutics Inc AKBA Vafseo ( vadadustat ) tablets for anemia due to chronic kidney disease ( CKD ) in adults who have been receiving dialysis for at least three months.
